Post
AviadoBio treats first subject in trial of FTD-GRN therapy
UK-based biotechnology company AviadoBio has administered its investigational gene therapy, AVB-101, to the first subject in the Phase I/II ASPIRE-FTD …
Novartis reports data from trial of IgA nephropathy treatment
Swiss pharmaceutical company Novartis has published pre-specified interim analysis results from the Phase III APPLAUSE-IgAN clinical trial of Fabhalta (iptacopan) …
Phaxiam enrols first patient in endocarditis infection study
Phaxiam Therapeutics has announced the enrolment of the first patient to a Phase I trial on the treatment of endocarditis …
Marinus fails to meet early stopping criteria for status epilepticus trial
Marinus Pharmaceuticals has announced that its pivotal Phase III RAISE study (NCT04391569) of IV ganaxolone for the treatment of status …
IT and bioinformatics companies for the clinical trials industry
Digitalising clinical trials can improve accessibility and engagement for participants, as well as data collection and analytics. It has the …
AAN 2024: AbbVie and NeuroDerm highlight benefits of levodopa infusions in hope of US launch
At the American Academy of Neurology (AAN) 2024 Annual Meeting, further data on AbbVie’s Produodopa/Vyalev and NeuroDerm’s ND0612 (levodopa/carbidopa) were …
Study explores the effects of state Medicaid policies on hepatitis C treatment
The treatment of the hepatitis C virus (HCV) has been a controversial subject of health policy in the US, spurring …
Arrowhead Pharmaceuticals presents new Phase II data at the American College of Cardiology 2024
At the American College of Cardiology Scientific Sessions & Expo 2024 in Atlanta, Arrowhead Pharmaceuticals recently unveiled final data from …
AviadoBio treats first subject in trial of FTD-GRN therapy
UK-based biotechnology company AviadoBio has administered its investigational gene therapy, AVB-101, to the first subject in the Phase I/II ASPIRE-FTD …
Novartis reports data from trial of IgA nephropathy treatment
Swiss pharmaceutical company Novartis has published pre-specified interim analysis results from the Phase III APPLAUSE-IgAN clinical trial of Fabhalta (iptacopan) …
Phaxiam enrols first patient in endocarditis infection study
Phaxiam Therapeutics has announced the enrolment of the first patient to a Phase I trial on the treatment of endocarditis …
Marinus fails to meet early stopping criteria for status epilepticus trial
Marinus Pharmaceuticals has announced that its pivotal Phase III RAISE study (NCT04391569) of IV ganaxolone for the treatment of status …
IT and bioinformatics companies for the clinical trials industry
Digitalising clinical trials can improve accessibility and engagement for participants, as well as data collection and analytics. It has the …
Sanofi advances NK cell engager to Phase II for blood cancer treatment
Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use …
EMulate’s radiofrequency device proves effective in GBM mouse models
Seattle-based device company EMulate Therapeutics has announced that a study proving the effectiveness of its radiofrequency energy device in mouse …